Efficacy of chemotherapy after progression with nivolumab in squamous cell carcinoma of the head and neck

被引：7
|
作者：
Suzuki, Shinsuke [1 ]
Toyoma, Satoshi [1 ]
Tomizawa, Hiroki [1 ]
Yamada, Toshiki [1 ]
Iikawa, Nobuko [1 ]
Shiina, Kazuhiro [1 ]
Saito, Hidekazu [1 ]
Koizumi, Koh [1 ]
Kawasaki, Yohei [1 ]
Yamada, Takechiyo [1 ]
机构：
[1] Akita Univ, Dept Otorhinolaryngol & Head & Neck Surg, Grad Sch Med, Akita 0108543, Japan
来源：
AURIS NASUS LARYNX | 2020年 / 47卷 / 03期
关键词：
Head and neck squamous cell carcinoma; Immune checkpoint inhibitor; Nivolumab; Chemotherapy; Recurrence; Metastasis; INVESTIGATORS CHOICE; RESPONSE RATES; RECURRENT; INHIBITORS; CETUXIMAB; THERAPY; CANCER; TRIAL;
D O I：
10.1016/j.anl.2019.06.004
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
Nivolumab, a programmed death-1 (PD-1) inhibitor, has shown promising results against squamous cell carcinoma of the head and neck (SCCHN) in cases of recurrence or in a metastatic setting after platinum-based therapy. However, treatment alternatives for patients with nivolumab-refractory are limited, and a constant opinion is not provided. Recently, accumulating studies have demonstrated that chemotherapy after immune checkpoint inhibitor treatment may induce better objective responses in patients with advanced non-small cell lung cancer. However, there are few reports on the increased effect of chemotherapy after nivolumab treatment in SCCHN. Therefore, cases must be accumulated to identify patients with nivolumab-refractory SCCHN who may benefit from chemotherapy. Here, we present patients with SCCHN who exhibited a significant response to chemotherapy after nivolumab treatment. (C) 2019 Elsevier B.V. All rights reserved.
引用
收藏
页码：485 / 488
页数：4
相关论文
共 50 条
  • [1] Analysis of the benefit of salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck
    Reverdy, Thibaut
    Varnier, Romain
    de Talhouet, Solene
    Duplomb, Sophie
    Bruyas, Amandine
    ORAL ONCOLOGY, 2023, 145
  • [2] Nivolumab in squamous cell carcinoma of the head and neck
    Specenier, Pol
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (05) : 409 - 420
  • [3] Salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck included in the phase II TOPNIVO trial
    Saleh, K.
    Texier, M.
    Iacob, M.
    Daste, A.
    Fayette, J.
    Lefebvre, G.
    Saada, E. B.
    Zanetta, S.
    Vinches, M.
    Toullec, C.
    Salas, S.
    Kaminsky-Forrett, M-C.
    Johnson, A. C.
    Sire, C.
    Khalife-saleh, N.
    Ferrand, F. R.
    Monard, L.
    Auperin, A.
    Even, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S591 - S591
  • [4] Salvage chemotherapy after progression on immunotherapy in recurrent/metastatic squamous cell head and neck carcinoma
    Llop, Sandra
    Plana, Maria
    Tous, Sara
    Ferrando-Diez, Angelica
    Brenes, Jesus
    Juarez, Marc
    Vidales, Zara
    Vilajosana, Esther
    Linares, Isabel
    Arribas, Lorena
    Duch, Maria
    Fulla, Marta
    Brunet, Aina
    Lozano, Alicia
    Cirauqui, Beatriz
    Mesia, Ricard
    Oliva, Marc
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [5] Efficacy of Paclitaxel-based Chemotherapy After Progression on Nivolumab for Head and Neck Cancer
    Sato, Yasuyoshi
    Fukuda, Naoki
    Fujiwara, Y. U.
    Wang, Xiaofei
    Urasaki, Tetsuya
    Ohmoto, Akihiro
    Nakano, Kenji
    Ono, Makiko
    Tomomatsu, Junichi
    Mitani, Hiroki
    Takahashi, Shunji
    IN VIVO, 2021, 35 (02): : 1211 - 1215
  • [6] Antibiotics may interfere with nivolumab efficacy in patients with head and neck squamous cell carcinoma
    Ueta, Reio
    Imai, Hiroo
    Saijo, Ken
    Kawamura, Yoshifumi
    Kodera, Shuto
    Komine, Keigo
    Ouchi, Kota
    Kasahara, Yuki
    Taniguchi, Sakura
    Yoshida, Yuya
    Sasaki, Keiju
    Shirota, Hidekazu
    Takahashi, Masanobu
    Ishioka, Chikashi
    ONCOLOGY, 2024, 102 (03) : 252 - 259
  • [7] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
    Ferris, R. L.
    Blumenschein, G., Jr.
    Fayette, J.
    Guigay, J.
    Colevas, A. D.
    Licitra, L.
    Harrington, K.
    Kasper, S.
    Vokes, E. E.
    Even, C.
    Worden, F.
    Saba, N. F.
    Iglesias Docampo, L. C.
    Haddad, R.
    Rordorf, T.
    Kiyota, N.
    Tahara, M.
    Monga, M.
    Lynch, M.
    Geese, W. J.
    Kopit, J.
    Shaw, J. W.
    Gillison, M. L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19): : 1856 - 1867
  • [8] Nivolumab for recurrent squamous-cell carcinoma of the head and neck
    British Dental Journal, 2016, 221 (10) : 632 - 632
  • [9] Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma
    Wakasaki, Takahiro
    Yasumatsu, Ryuji
    Uchi, Ryutaro
    Taura, Masahiko
    Matsuo, Mioko
    Komune, Noritaka
    Nakagawa, Takashi
    AURIS NASUS LARYNX, 2020, 47 (01) : 116 - 122
  • [10] Efficacy and safety of nivolumab for previously treated non-squamous cell carcinoma of the head and neck
    Suzuki, Chiaki
    Kiyota, Naomi
    Imamura, Yoshinori
    Rikitake, Junpei
    Sai, Satoshi
    Kimbara, Shiro
    Hyogo, Yasuko
    Nagatani, Yoshiaki
    Funakoshi, Yohei
    Toyoda, Masanori
    Minami, Hironobu
    ANNALS OF ONCOLOGY, 2018, 29
12345